Table 3.
Recommendations for Human Papillomavirus Vaccination From the Advisory Committee on Immunization Practices and the World Health Organization
| Yeara | Recommendations | HPV Vaccinesb |
|---|---|---|
| ACIP | (Available in the United States) | |
| 2006 [101] | Females: routine vaccination with a 3-dose schedule at age 11 or 12 y; series can be started at age 9 y; vaccination recommended through age 26 y for those not vaccinated previously | Gardasil |
| 2009 [102] | Females: recommendations as in 2006 Males: may be vaccinated at age 9–26 y |
Gardasil, Cervarix |
| 2011 [103] | Females: Recommendations as in 2006 Males: Routine vaccination at age 11 or 12 y with Gardasil; series can be started at age 9 y; vaccination recommended through age 21 y in those not vaccinated previously and through age 26 y for men who have sex with men and persons with immunocompromising conditions, including HIV |
Gardasil, Cervarix |
| 2015 [104] | Gardasil 9 recommended as a vaccine that can be used for females and males | Gardasil, Cervarix, Gardasil 9 |
| 2016 [105] | 2-dose schedule, if starting series at age 9–14 y; 3-dose schedule for older age groups and for persons with immunocompromising conditions | Gardasil, Cervarix, Gardasil 9 |
| 2019 [106] | Vaccination recommended through age 26 y, for those not vaccinated previously; shared clinical decision making for persons aged 27–45 y | Gardasil 9 |
| WHO | (Available through Gavi) | |
| 2009 [107] | Routine vaccination of a single birth cohort of girls aged 9–13 y with a 3-dose schedule | Gardasil, Cervarix |
| 2014 [108] | 2-dose schedule, if starting series at age 9–14 y; 3-dose schedule for older girls/women or for immunocompromised persons | Gardasil, Cervarix |
| 2017 [109] | Vaccination of multiple cohorts of girls aged 9–14 y when vaccine first introduced; vaccination of other populations (females aged ≥15 y or males), only if feasible, affordable, cost-effective, and not diverting resources from primary target population or from cervical cancer screening programs | Gardasil, Cervarix |
| 2019 [110] | Owing to the global vaccine supply/demand imbalance, target girls aged 13 or 14 y, before they age out of the recommended primary target population, or schedule an extended interval of 3–5 y between the 2 doses, with dose 1 given to girls aged 9 or 10 y | Gardasil, Cervarix |
Abbreviations: ACIP, Advisory Committee on Immunization Practices; Gavi, The Vaccine Alliance (Gavi); HIV, human immunodeficiency virus; HPV, human papillomavirus; WHO, World Health Organization.
aYear of vote by ACIP or decision by WHO or WHO’s Strategic Advisory Group of Experts on Immunization.
bNo preference stated for any vaccine. Gardasil is a quadrivalent, Cervarix a bivalent, and Gardasil 9 a nonavalent HPV vaccine.